You are here

gene therapy

Biogen backs away from AGTC after gene therapy failure

Biogen backs away from AGTC after gene therapy failure

BioPharma Dive

Applied Genetic Technologies

Flag link:

Biogen bails on AGTC after ocular gene therapy flunks trial

Biogen bails on AGTC after ocular gene therapy flunks trial

Fierce Biotech

Applied Genetic Technologies

rAAV2tYF-CB-hRS1

Flag link:

Axovant axes neuroscience drug, focuses on gene therapies

Axovant axes neuroscience drug, focuses on gene therapies

Pharmaforum

Flag link:

Angina gene therapy company XyloCor raises $17M series A round

Angina gene therapy company XyloCor raises $17M series A round

BioCentury

XyloCor Therapeutics

Flag link:

Nearly 300 gene and cell therapies in development – report

Nearly 300 gene and cell therapies in development – report

Pharmaforum

drug development

Flag link:

Novartis’ SMA Gene Therapy Is on the Fast Track for Approval

Novartis’ SMA Gene Therapy Is on the Fast Track for Approval

BioSpace

priority review

Flag link:

Novartis CEO Vas Narasimhan On The Price Of Gene Therapies: 'It's A Challenge We Have To Solve'

Novartis CEO Vas Narasimhan On The Price Of Gene Therapies: 'It's A Challenge We Have To Solve'

Forbes

Flag link:

Biotech Showcase Conference Reveals Six Therapeutic Areas Receiving the Most Investment Attention in 2019

Biotech Showcase Conference Reveals Six Therapeutic Areas Receiving the Most Investment Attention in 2019

CP Wire

Alzheimer's disease

immuno-oncology

orphan diseases

Flag link:

Biotech Showcase Conference Reveals Six Therapeutic Areas Receiving the Most Investment Attention in 2019

Alzheimer's disease

immuno-oncology

orphan diseases

Flag link:

Luxturna cleared for sale in Europe, but payer support uncertain

Luxturna cleared for sale in Europe, but payer support uncertain

Biopharma Dive

Spark Therapeutics

Flag link:

Rolling up its sleeves, Axovant scoops up five gene therapy vets to propel new pipeline

Rolling up its sleeves, Axovant scoops up five gene therapy vets to propel new pipeline

Endpoints

Flag link:

Novartis/Spark’s sight gene therapy approved in EU

Novartis/Spark’s sight gene therapy approved in EU

Pharmaforum

Spark Therapeutics

Flag link:

UniQure’s hemophilia B gene therapy achieves 31% FIX activity

UniQure’s hemophilia B gene therapy achieves 31% FIX activity

Fierce Biotech

Flag link:

Myonexus Therapeutics Starts Trial of First-Ever Gene Therapy for Rare Type of Muscular Dystrophy

Myonexus Therapeutics Starts Trial of First-Ever Gene Therapy for Rare Type of Muscular Dystrophy

CP Wire

Sarepta Therapeutics

muscular dystrophy

Flag link:

Researchers Cure ALS in Laboratory Animals Using Gene Therapy

Researchers Cure ALS in Laboratory Animals Using Gene Therapy

BioSpace

Lou Gehrig's disease

University of California

Flag link:

Look how far precision medicine has come

Look how far precision medicine has come

MIT Technology Review

precision medicine

personlized medicine

Flag link:

New York biotech snaps up Eli Lilly neuro veteran as CSO

New York biotech snaps up Eli Lilly neuro veteran as CSO

Fierce Biotech

Redpin Therapeutics

Flag link:

Selecta's rapamycin nanoparticles could enable re-dosing of gene therapies

Selecta's rapamycin nanoparticles could enable re-dosing of gene therapies

BioCentury

Selectra Biosciences

Flag link:

Sarepta Gene Therapy Appears To Help Fourth Boy With Duchenne Muscular Dystrophy

Sarepta Gene Therapy Appears To Help Fourth Boy With Duchenne Muscular Dystrophy

Forbes

Sarepta Therapeutics

Duchenne Muscular Dystrophy

Flag link:

[video+transcript]Gene Therapy Could Be a Boon for This Biotech

[video+transcript]Gene Therapy Could Be a Boon for This Biotech

Motley Fool

spinal muscular atrophy

wet age-related macular degeneration

Flag link:

Pages